Performance analysis of Neoleukin Therapeutics (NGNE)
Annual Return
Over the past 3 years, NGNE has had an average annual return of +38.25%, outperforming the benchmark SPY, which returned +19.62% annual.
Over the past 5 years, NGNE has had an average annual return of -25.84%, underperforming the benchmark SPY, which returned +12.73% annual.
Over the past 10 years, NGNE has had an average annual return of -13.46%, underperforming the benchmark SPY, which returned +15.04% annual.
Since Mar 7, 2014, NGNE has had an average annual return of -14.05%, underperforming the benchmark SPY, which returned +13.72% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| +78.07% | -9.83% | +17.88% | +90.38% | -89.44% | -65.82% | +14.44% | +470.24% | -81.63% | -28.77% | +32.29% | +66.41% |
| 2014 | |||||||||||
| -37.24% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.27% | +33.02% | -14.14% | +29.38% | +8.61% | +10.96% | +16.64% | +78.07% | |||||
| 2025 | -30.65% | +11.61% | -33.78% | +28.16% | +13.38% | -12.08% | +45.53% | -15.15% | -6.21% | +97.66% | -38.45% | -2.27% | -9.83% |
| 2024 | +55.61% | +3.01% | +63.85% | -32.25% | +9.01% | -3.18% | +13% | -9.01% | +12.13% | +4.84% | -42.21% | -10.15% | +17.88% |
| 2023 | +16.90% | -15.46% | +39.19% | +27.65% | -10.56% | +3.89% | -16.98% | +9.19% | +4.92% | -14.37% | +2.30% | +40.07% | +90.38% |
| 2022 | -25.94% | -27.72% | -27.14% | -35.09% | -18.02% | +2.99% | -1.97% | +2.01% | -37.82% | -11.19% | -10.29% | -0.23% | -89.44% |
| 2021 | -10.64% | -4.45% | +2.24% | +1.47% | -19.70% | -7.97% | -24.27% | +16.60% | -11.29% | +1.39% | -26.88% | -10.08% | -65.82% |
| 2020 | +0.32% | -21.52% | +17.32% | -2.11% | +9.33% | +36.29% | -41.69% | +31.31% | -5.58% | -12.59% | +20.97% | +11.11% | +14.44% |
| 2019 | +6.47% | +14.75% | +2.08% | -0.93% | -2.24% | -9.57% | +13.11% | +25.11% | -14.67% | +4.57% | +87.21% | +120.82% | +470.24% |
| 2018 | +9.95% | +12.07% | -2.84% | -13.42% | +17.64% | -81.52% | +11.68% | +5.41% | -6.09% | -11.95% | -8.15% | -8.83% | -81.63% |
| 2017 | +9.39% | -4.32% | -3.41% | -12.04% | -13.08% | +10.26% | +0.50% | +3.32% | -2.88% | -20.57% | -6.30% | +11.36% | -28.77% |
Drawdown analysis of Neoleukin Therapeutics (NGNE)
The maximum drawdown for the NGNE was -98.34%, occurring on Apr 8, 2025. This drawdown has not yet recovered.
The current NGNE drawdown is -91.71%.
Since Mar 7, 2014 NGNE has experienced the following drawdowns:
- 50% or more: 2 times
- 40% or more: 2 times
- 30% or more: 2 times
- 20% or more: 2 times
- 10% or more: 3 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -98.34% | Aug 14, 2015 | 2426 | Apr 8, 2025 | Ongoing | Ongoing | Ongoing |
| -89.57% | Mar 12, 2014 | 346 | Jul 27, 2015 | 10 | Aug 10, 2015 | 356 |
| -16.19% | Aug 11, 2015 | 1 | Aug 12, 2015 | 2 | Aug 14, 2015 | 3 |